Guidance - Spark Newswire

1 minute read

Arcosa Q2 Adj. EPS $0.60 Beats $0.57 Estimate, Sales $515.10M Beat $491.65M Estimate; Reaffirms FY21 Adj. EBITDA $270M-$290M

Today, 8:24 PM

Arcosa (NYSE:ACA) reported quarterly earnings of $0.60 per share which beat the analyst consensus estimate of $0.57 by 5.26 percent. This is a 17.81 percent decrease over earnings of $0.73 per share from the same period

ACA

3 minute read

Ceridian Sees FY21 Sales $1.008B-$1.018B vs $1B Est., Sees Q3 Sales $251M-$255M vs $252.45M Est.

By Bill Haddad

Today, 8:24 PM

Business Outlook Based on information available as of August 4, 2021, Ceridian has issued the following guidance for the remainder of fiscal year

CDAY

1 minute read

Tutor Perini Q2 EPS $0.61 Beats $0.51 Estimate, Sales $1.22B Miss $1.24B Estimate; Reaffirms Guidance

By Benzinga Newsdesk

Today, 8:24 PM

Tutor Perini (NYSE:TPC) reported quarterly earnings of $0.61 per share which beat the analyst consensus estimate of $0.51 by 19.61 percent. This is a 64.86 percent increase over earnings of $0.37 per share from the same

TPC

1 minute read

Globus Medical Sees FY21 Adj. EPS $1.89-$2.00 vs $1.89 Est., Sales $925M-$950M vs $926.78M Est.

By Bill Haddad

Today, 8:24 PM

The Company today increased guidance for full year 2021 net sales from $925 million to $950 million and non-GAAP diluted earnings per share of $1.89 to $2.00.

GMED

1 minute read

Barrett Business Services Q2 Adj. EPS $2.24 Beats $1.50 Estimate, Sales $233.20M Beat $224.15M Estimate; Raises FY21 Gross Billings Growth Guidance From 5-7% To 6-8% Year Over Year

By Benzinga Newsdesk

Today, 8:24 PM

Barrett Business Services (NASDAQ:BBSI) reported quarterly earnings of $2.24 per share which beat the analyst consensus estimate of $1.50 by 49.33 percent. This is a 48.34 percent increase over earnings of $1.51 per

BBSI

1 minute read

CVRx Sees Q3 Sales $3.3M-$3.6M, Sees FY21 Sales $13.3M-$13.9M

By Bill Haddad

Today, 8:24 PM

Business Outlook For the full year of 2021, the Company expects: Total revenue between $13.3 million and $13.9 million; Gross margin between 72.0% and 74.0%; Operating expenses between $34.0 million and $36.0

CVRX

1 minute read

Nevro Sees Q3 Sales $90M-$93M vs $115.35M Est.

By Bill Haddad

Today, 8:24 PM

2021 Outlook Nevro continues to monitor and evaluate the impact the global response to the COVID pandemic has had, and will continue to have, on its operations and financial results. Due to the uncertainties

NVRO

2 minute read

Amedisys Sees FY21 Core Adj. EPS $6.37-$6.49, Adj. Service Revenue $2.23B-$2.245B; Says ‘our Hospice segment is behind in both admission and average daily census growth’

By Bill Haddad

Today, 8:24 PM

Updated 2021 Guidance While our performance in the first half of 2021 has produced strong EBITDA and expanded margins, our Hospice segment is behind in both admission and average daily census growth. The COVID-19

AMED

1 minute read

Stantec Q2 Adj. EPS $0.62 Beats $0.35 Estimate, Sales $908.30M Beat $693.81M Estimate; Raises Guidance

By Benzinga Newsdesk

Today, 8:24 PM

Stantec (NYSE:STN) reported quarterly earnings of $0.62 per share which beat the analyst consensus estimate of $0.35 by 77.14 percent. This is a 63.16 percent increase over earnings of $0.38 per share from the same

STN

1 minute read

10x Genomics Q2 EPS $(0.10) Beats $(0.26) Estimate, Sales $115.85M Beat $112.85M Estimate; Reaffirms FY21 Sales Guidance $480M-$500M vs $496.5M Est.

By Benzinga Newsdesk

Today, 8:24 PM

10x Genomics (NASDAQ:TXG) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.26) by 61.54 percent. This is a 75.61 percent increase over losses of $(0.41) per share from the

TXG